Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan
The Journal of Clinical Endocrinology & Metabolism · 15.10.2024 · 109 (11) · 2784-2792
DOI: 10.1210/clinem/dgae271 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 17.04.2024. Verfasst von Soji Toda und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa 241-8515, Japan. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Databases, Factual, Phenylurea Compounds. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Context
The relationship between the genomic profile and prognosis of advanced thyroid carcinoma requiring drug therapy has not been reported.
Objective
To evaluate the treatment period and overall survival time for each genetic alteration in advanced thyroid carcinoma that requires drug therapy.
Methods
We conducted a retrospective observational study using a national database in Japan, which included 552 cases of thyroid carcinoma out of 53 543 patients in the database.
Results
The database included anaplastic thyroid carcinoma (23.6%), poorly differentiated thyroid carcinoma (10.0%), and differentiated thyroid carcinoma (66.4%). The most common genetic abnormalities were TERT promoter (66.3%), BRAF (56.7%), and TP53 (32.2%). The typical driver genes were BRAF V600E (55.0%), RAS (18.5%), RET fusion (4.7%), NTRK fusion (1.6%), and ALK fusion (0.4%). The most common regimen was lenvatinib, and the time to treatment failure was not different despite the presence of BRAF or RAS mutations. In differentiated thyroid carcinoma and poorly differentiated thyroid carcinoma, TP53 alterations independently predicted worse overall survival (hazard ratio = 2.205, 95% confidence interval: 1.135-4.283). In anaplastic thyroid carcinoma, no genetic alterations were associated with overall survival.
Conclusion
Genetic abnormalities with treatment options were found in 62.7% of advanced thyroid carcinomas. TP53 abnormality was an independent poor prognostic factor for overall survival in differentiated thyroid carcinoma. The time to treatment failure for lenvatinib was not different based on genetic profile.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrine Surgery, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
- Department of Breast and Thyroid Surgery, Yokohama City University Medical Center, Kanagawa 232-0024, Japan.
- Department of Cancer Genome Medicine, Kanagawa Cancer Center, Kanagawa 241-8515, Japan.
- Research Institute Division of Advanced Cancer Therapeutics, Kanagawa Cancer Center Research Institute, Kanagawa 241-8515, Japan.
ORCID-Profile: Soji Toda, Hiroyuki Iwasaki
Zitieren
APA
Toda, S., Hiroshima, Y., Iwasaki, H., & Masudo, K. (2024). Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan. The Journal of Clinical Endocrinology & Metabolism, 109(11), 2784-2792. https://doi.org/10.1210/clinem/dgae271
Vancouver
Toda S, Hiroshima Y, Iwasaki H, Masudo K. Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan. The Journal of Clinical Endocrinology & Metabolism. 2024;109(11):2784-2792. doi:10.1210/clinem/dgae271
BibTeX
@article{Toda2024,
author = {Toda, Soji and Hiroshima, Yukihiko and Iwasaki, Hiroyuki and Masudo, Katsuhiko},
title = {Genomic Landscape and Clinical Features of Advanced Thyroid Carcinoma: A National Database Study in Japan},
journal = {The Journal of Clinical Endocrinology & Metabolism},
year = {2024},
volume = {109},
number = {11},
pages = {2784--2792},
doi = {10.1210/clinem/dgae271}
}
EUVIMED